financetom
Business
financetom
/
Business
/
EHealth Names Derrick Duke as Next CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EHealth Names Derrick Duke as Next CEO
Jul 29, 2025 7:36 AM

10:22 AM EDT, 07/29/2025 (MT Newswires) -- EHealth ( EHTH ) said Tuesday that Derrick Duke has been named as its next chief executive officer to succeed Fran Soistman, who is retiring from the post.

Duke will join the company on Aug. 4 to start the transition process before officially taking on the CEO role, while Soistman agreed to remain as an executive advisor through Dec. 31 to assist with the transition, the company said.

Duke is currently the CEO of Magellan Health, a Centene (CNC) subsidiary, according to the statement.

Price: 3.94, Change: +0.02, Percent Change: +0.51

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
United States Antimony Stock Gains On Massive Revenue Beat
United States Antimony Stock Gains On Massive Revenue Beat
Mar 20, 2026
United States Antimony ( UAMY ) shares are trading higher Friday after the company reported fourth-quarter financial results on Thursday after the market closed. United States Antimony ( UAMY ) stock is among today’s top performers. Why are UAMY shares rallying? Revenue Surges Despite EPS Miss United States Antimony ( UAMY ) reported a loss of 4 cents per share, missing...
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
Mar 20, 2026
The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). The FDA also approved Imcivree (setmelanotide) in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome or Pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency. FDA Expands...
Market Chatter: Silgan Indicates Interest in Germany's Gerresheimer
Market Chatter: Silgan Indicates Interest in Germany's Gerresheimer
Mar 20, 2026
09:44 AM EDT, 03/20/2026 (MT Newswires) -- Silgan ( SLGN ) has indicated interest in acquiring German medical packaging firm Gerresheimer, Reuters reported Friday, quoting two unnamed sources familiar with the situation. The US packaging company is working with advisers, the report said, adding that there is no certainty there will be a bid and that a deal will materialize....
Form 8.3
Form 8.3
Mar 20, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: First Trust Advisors L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved